Standard BioTools Inc. (NASDAQ:LAB) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 433.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,128 shares of the company’s stock after buying an additional 14,732 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Standard BioTools were worth $35,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Standard BioTools by 215.3% during the first quarter. Vanguard Group Inc. now owns 13,034,043 shares of the company’s stock worth $35,322,000 after buying an additional 8,900,104 shares during the last quarter. Swiss National Bank acquired a new position in shares of Standard BioTools during the 1st quarter valued at about $1,162,000. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Standard BioTools by 20.2% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,642,271 shares of the company’s stock valued at $18,837,000 after purchasing an additional 1,788,780 shares during the period. Rhumbline Advisers increased its position in Standard BioTools by 3,691.1% during the second quarter. Rhumbline Advisers now owns 407,467 shares of the company’s stock worth $721,000 after purchasing an additional 396,719 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Standard BioTools by 1,019.8% during the second quarter. Bank of New York Mellon Corp now owns 980,983 shares of the company’s stock worth $1,736,000 after purchasing an additional 893,383 shares during the period. 53.74% of the stock is owned by hedge funds and other institutional investors.

Standard BioTools Trading Down 1.4 %

NASDAQ LAB opened at $2.15 on Friday. The stock has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $2.08. The stock has a market cap of $797.98 million, a PE ratio of -3.03 and a beta of 1.57. Standard BioTools Inc. has a twelve month low of $1.21 and a twelve month high of $3.04.

Insider Buying and Selling at Standard BioTools

In related news, Director Casdin Partners Master Fund, L bought 150,000 shares of the stock in a transaction on Monday, August 26th. The stock was bought at an average price of $2.15 per share, with a total value of $322,500.00. Following the completion of the purchase, the director now directly owns 53,775,821 shares in the company, valued at $115,618,015.15. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 2,892,100 shares of company stock valued at $5,085,173 over the last 90 days. 53.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, TD Cowen cut their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a report on Thursday, October 31st.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.